Introduction {#s1}
============

MicroRNAs are thought to control cellular responses to stresses such as tissue damage and transformation ([@bib19]; [@bib4]), but the impact of this idea is unclear because microRNAs have been understudied in vivo. *let-7* is one of the most ancient and omnipresent microRNAs, yet relatively little is known about its functional roles in mammalian development and physiology. *let-7* was first identified as a gene that regulates the timing of developmental milestones in a *C. elegans* screen ([@bib30]). In mammals, mature *let-7* is undetectable in early embryos and embryonic stem cells, but becomes highly expressed in most adult tissues ([@bib31]; [@bib35]). A handful of previous studies have implicated *let-7* in body size regulation, metabolism, stem cell self-renewal, and colon carcinogenesis ([@bib49]; [@bib8]; [@bib33]; [@bib26]; [@bib21], but the core functions of *let-7* in regeneration and disease remain incompletely understood.

In addition to questions about what *let-7* does, it is unknown why so many *let-7s* are expressed at such high levels. In mice and humans, the *let-7* family is comprised of 10 to 12 members who are thought to share a common set of mRNA targets. It has been thought that deep redundancy might make it difficult to discern any phenotypes that individual *let-7*s might have. Essential unanswered questions regarding *let-7* biology include whether *let-7* members are redundant, have unique functions, or are regulated to maintain a specific total dose. Our previous study of Lin28a, which inhibits the biogenesis of each *let-7* member similarly ([@bib11]; [@bib24]), suggests that total *let-7* dose alterations, rather than regulation of specific members, is important. In transgenic mice, modest increase in *Lin28a* and consequent 40% suppression of total *let-7* levels promote increased glucose uptake and an overgrowth syndrome ([@bib48]).

In this study we examined the consequences of *let-7* dose disruption in cancer and organ regeneration in genetic mouse models. While *let-7s* have been implicated as a tumor suppressor, this has predominantly been shown in cell lines and xenograft assays ([@bib9]; [@bib1]; [@bib13]; [@bib41]; [@bib42]; [@bib17]), as well as using exogenous *let-7* delivery to mouse cancer models ([@bib7]; [@bib38]; [@bib39]). Here, we confirmed the tumor suppressor activity of an endogenous transgenic *let-7* in a *MYC-*driven hepatoblastoma model. However, we found that this same level of *let-7* overexpression impaired liver regeneration after partial hepatectomy (PHx). Furthermore, chronic high-dose *let-7* resulted in severe liver damage and paradoxical liver cancer development. Overall, we provide in vivo evidence that *let-7* expression levels have been developmentally constrained to balance the need for regenerative proliferation against the need to antagonize malignant proliferation, findings with implications for *let-7* based therapies.

Results {#s2}
=======

*let-7g* inhibits the development of *MYC*-driven hepatoblastoma {#s2-1}
----------------------------------------------------------------

To study the effect of *let-7* on carcinogenesis, we employed an inducible *MYC-*driven hepatoblastoma model ([@bib32]). In this model, most *let-7*s are suppressed by more than 60% ([@bib25]). However, *MYC* affects the expression of many other microRNAs ([@bib1]; [@bib15]). To test if *let-7* suppression is specifically required for *MYC's* oncogenic program, we simultaneously overexpressed *let-7g* and *MYC* using a triple transgenic, liver-specific, tet-off model ([Figure 1A](#fig1){ref-type="fig"}: *LAP-tTA; TRE-MYC; TRE-let-7S21L* transgenic mice). This transgenic form of *let-7g* is an engineered *let-7* species called *let-7S21L (let-7g* [S]{.ul}tem + *miR-[21]{.ul}* [L]{.ul}oop) ([@bib49]), in which the precursor microRNA loop derives from *mir-21* and cannot be bound and inhibited by Lin28b ([Figure 1B](#fig1){ref-type="fig"}), which is highly expressed in *MYC*-driven tumors ([@bib1]; [@bib25]).10.7554/eLife.09431.003Figure 1.*let-7g* inhibits the development of *MYC*-driven hepatoblastoma.(**A**) Schema of the liver-specific inducible *LAP-MYC* +/- *let-7S21L* cancer model. (**B**) *let-7S21L* is a chimeric construct containing the *let-7g* stem, *miR-21* loop, and *let-7g* flanking sequences. (**C**) Schema showing that *LAP-MYC* +/- *let-7S21L* mice were induced at 14 days of age, tissues were collected at 90 days of age, and survival was followed. (**D**) Ninety-day old mice bearing tumors in the *LAP-MYC* (87.5%, 7/8) and *LAP-MYC + let-7S21L* (27.3%, 3/11) mouse models. (**E**) Livers showing tumors from the above mice. (**F**) Liver surface area occupied by tumor. (**G**) Kaplan-Meier curve of *LAP-MYC* alone and *LAP-MYC + let-7S21L* mice. (**H**) Mature *let-7* expression levels in as determined by RT-qPCR. (**I**) Human *c-MYC* mRNA expressionin tumors as determined by RT-qPCR. (**J**) Heat map of *let-7* target gene expression in WT normal livers, *MYC* tumors, and *MYC* + *let-7S21L* tumors as measured by RT-qPCR. Red is higher and blue is lower relative mRNA expression. (**K**) Gene expression plotted as bar graphs to show relative changes. (**L**) Evolutionarily conserved *let-7* target sites within 3'UTRs (Targetscan.org). All data in this figure are represented as mean ± SEM. \*p \< 0.05, \*\*p \< 0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.09431.003](10.7554/eLife.09431.003)10.7554/eLife.09431.004Figure 1---figure supplement 1.H&E staining of *LAP-MYC* and *LAP-MYC + let-7S21L* tumor-adjacent normal tissues and tumor tissues.**DOI:** [http://dx.doi.org/10.7554/eLife.09431.004](10.7554/eLife.09431.004)

Induction of *MYC* with or without *let-7S21L* was initiated at 14 days of age ([Figure 1C](#fig1){ref-type="fig"}). By 90 days of age, large multifocal tumors had formed in 88% of the *MYC* alone group, whereas single small tumors appeared in only 27% the *MYC* + *let-7S21L* group ([Figure 1D--F](#fig1){ref-type="fig"}) and overall survival was dramatically improved ([Figure 1G](#fig1){ref-type="fig"}). The level of *let-7g* was increased more than eightfold in both non-tumor and tumor tissues ([Figure 1H](#fig1){ref-type="fig"}). Tumors from both groups showed similar histology ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) and *MYC* expression ([Figure 1I](#fig1){ref-type="fig"}). Gene-expression within tumors showed that previously validated *let-7* targets involved in proliferation and growth including *Cdc25a* ([@bib14] *Cdc34* ([@bib18]), *E2f2* ([@bib5]), *E2f5* ([@bib16]), and *Map4k4* ([@bib34]) were upregulated in *MYC*-tumors, but suppressed back down to normal levels in the context of *let-7* overexpression ([Figure 1J--L](#fig1){ref-type="fig"}), suggesting that the repression of these targets restrains *MYC*-dependent tumorigenesis. These data indicated that *let-7g* has potent tumor suppressor activity in the context of *MYC*-driven hepatoblastoma.

*let-7g* overexpression inhibits liver regeneration after partial hepatectomy {#s2-2}
-----------------------------------------------------------------------------

Since increasing *let-7g* was extremely effective at suppressing hepatoblastoma without compromising overall health, we asked if this increase in levels would impact tissue homestasis. We examined *let-7g* overexpression in the setting of liver injuries that drive rapid proliferation and growth. After PHx, *let-7s* in regenerating tissues fell, but returned to normal after forty hours ([Figure 2A](#fig2){ref-type="fig"}), findings consistent with a previous report ([@bib3]). Similarly, *let-7s* also declined acutely after chemical injury with the xenobiotic TCPOBOP (1,4-bis-\[2-\[3,5-dichloropyridyloxy\]\] benzene) ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). This shows that while *let-7* increases in a temporally defined fashion during development ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}), it can transiently fluctuate after environmental perturbations. To test if the observed *let-7* suppression is necessary for regeneration, we induced *let-7g* in *LAP-let-7S21L* mice and performed PHx ([Figure 2B--D](#fig2){ref-type="fig"}). The body weight ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}), liver function ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}), resected liver mass ([Figure 2E](#fig2){ref-type="fig"}) and histology ([Figure 2---figure supplement 1E](#fig2){ref-type="fig"}) were unaffected in *LAP-let-7S21L* mice compared to control mice. Forty hours after PHx, there was reduced liver mass and decreased Ki-67 in *LAP-let-7S21L* mice ([Figure 2F--H](#fig2){ref-type="fig"}). Liver mass was no different at four and fourteen days, indicating a kinetic delay but not a permanent impairment ([Figure 2---figure supplement 1F,G](#fig2s1){ref-type="fig"}).10.7554/eLife.09431.005Figure 2.*let-7g* overexpression inhibits liver regeneration after partial hepatectomy.(**A**) Mature endogenous *let-7* expression levels in WT C57Bl/6 mice at different time points after PHx as determined by RT-qPCR (n=4 and 4 for each time point). (**B**) Schema of the *LAP-let-7S21L* dox-inducible model. *LAP-tTA* single transgenic mice served as the controls. (**C**) Schema showing that *let-7S21L* control and *LAP-let-7S21L* mice were induced at 42 days of age, PHx was performed after 14 days of induction, and tissues were collected 40 hr post PHx. (**D**) Mature *let-7* expression levels in *let-7S21L* and *LAP-let-7S21L* livers after 14 days of induction (n=4 and 4). (**E**) Resected liver/body weight ratios of *LAP-tTA* Control and *LAP-let-7S21L* mice at the time of PHx (n=4 and 4). (**F**) Liver/body weight ratios 40 hr after PHx (n=4 and 4). (**G**) Ki-67 staining on resected and post-PHx liver tissues. (**H**) Quantification of Ki-67-positive cells (n=2 and 2 mice; ten 20x fields for each mouse were quantified). (**I**) Resected liver/body weight ratios 2 days after intravenous injection of 0.5 mg/kg negative control or *let-7g* microRNA mimics packaged in C12-200 LNPs (n=5 and 5). (**J**) Liver/body weight ratios 40 hr after PHx (n=4 and 4). (**K**) Mature *let-7g* expression levels in mimic treated livers (n=5 and 5). All data in this figure are represented as mean ± SEM. \*p\<0.05, \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.09431.005](10.7554/eLife.09431.005)10.7554/eLife.09431.006Figure 2---figure supplement 1.Data associated with [Figure 2](#fig2){ref-type="fig"}.(**A**) Sum of the absolute sequencing reads for mature *let-7* microRNA family members after TCPOBOP treatment, as measured by small RNA sequencing. (**B**) Mature *let-7* microRNA family expression in WT mouse livers at different ages as determined by RT-qPCR. Numbers over bars indicate the fold change normalized to that of 1 day old mice. (**C**) Body weights of *let-7S21L* alone and *LAP-let-7S21L* mice pre-PHx (n=4 and 4). (**D**) Liver function tests: ALT (U/L) and AST (U/L) of *let-7S21L* alone and *LAP-let-7S21L* mice pre-PHx (n=5 and 5). (**E**) H&E staining of *let-7S21L* alone and *LAP-let-7S21L* mice pre-PHx. (**F**) Schema showing that *let-7S21L* control and *LAP-let-7S21L* mice were induced at 42 days of age, PHx was performed after 14 days of induction, and tissues were collected 4 and 14 days after PHx. (**G**) Liver to body weight ratio of *let-7S21L* alone and *LAP-let-7S21L* mice 4 and 14 days after PHx (n=5 and 5). All data in this figure are represented as mean ± SEM. \*p\<0.05, \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.09431.006](10.7554/eLife.09431.006)

To rule out increasing demands on microRNA biogenesis machinery as a mechanism of proliferative suppression, we delivered mature control or *let-7g* microRNA mimics (0.5 mg/kg) into wild-type mice two days prior to hepatectomy using C12-200 lipidoid nanoparticles (LNPs) ([@bib20]). *let-7g*, but not control mimics, inhibited regeneration ([Figure 2I--K](#fig2){ref-type="fig"}). While *let-7* overexpression blocked *MYC*-induced tumorigenesis, these data show that a similar increase in *let-7* levels inhibited post-injury organ growth and regeneration.

Loss of *let-7b* and *let-7c2* is sufficient to enhance liver regeneration {#s2-3}
--------------------------------------------------------------------------

To assess the physiological relevance of our gain-of-function experiments, we examined knockout mice to determine if *let-7* is a bona fide regeneration suppressor. Both *let-7b* and *let-7c2* were conditionally deleted from the liver by crossing *Albumin-Cre* into a *let-7b/c2 *floxed mouse (\"*let-7b/c2* LKO\" mice, [Figure 3A](#fig3){ref-type="fig"}). Small RNA-sequencing data from Xie et al. showed that *let-7* is one of the most highly expressed microRNA families in the liver and that *let-7b* and *let-7c2* together comprise approximately 18% of the *let-7* total ([Figure 3B](#fig3){ref-type="fig"}) ([@bib44]). Thus, *let-7b/c2* LKO mice have substantial, but far from a complete reduction of total *let-7* levels.10.7554/eLife.09431.007Figure 3.Loss of *let-7b* and *let-7c2* is sufficient to enhance liver regeneration.(**A**) Schema of liver-specific *let-7b* and *let-7c2* knockout mice (*let-7b/c2* LKO). *Albumin-Cre* excises loxPs in the embryonic liver of *let-7b/c2^Fl/Fl^* mice. Mice without *Cre* serve as the controls. (**B**) Small RNA sequencing showing the distribution of 10 *let-7s* in WT mice (n=2) (Data obtained from Xie et al. 2012). (**C**) Schema showing that PHx was performed on *let-7b/c2^Fl/Fl^ and let-7b/c2* LKO mice at 56 days of age and tissues were collected 40 hr post PHx. (**D**) Resected liver/body weight ratios at the time of PHx, and (**E**) Liver to body ratios of *let-7b/c2^Fl/Fl^* (n=11) and *let-7b/c2* LKO mice (n=10) 40 hr after PHx. (**F**) Ki-67 staining and (**G**) Quantification of Ki-67-positive cells on resected and 40 hr post-PHx liver tissues (n=3 and 3 mice; total of five 40x fields/mouse were used for quantification). (**H**) RT-qPCR on *let-7* family members from *let-7b/c2^Fl/Fl^* and *let-7b/c2* LKO mice pre- and 40 hr post-PHx. (**I**) Viability of H2.35 immortalized human hepatocytes treated with either scrambled, *let-7a*, or *let-7b* antiMiRs, measured at two and three days after transfection (n=10 each). All data in this figure are represented as mean ± SEM. \*p\<0.05, \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.09431.007](10.7554/eLife.09431.007)10.7554/eLife.09431.008Figure 3---figure supplement 1.Characterization of *let-7b/c2* LKO mice.(**A**) Body weight, liver weight, and liver to body weight percent of *let-7b/c2^Fl/Fl^* (n = 7) and *let-7b/c2* LKO mice (n=5) at 56 days of age. (**B**) H&E staining of *let-7b/c2^Fl/Fl^* (n=3) and *let-7b/c2* LKO livers (n=3). (**C**) Schema showing that PHx was performed on *let-7b/c2^Fl/Fl^ and let-7b/c2* LKO mice at 56 days of age and tissues were collected at 4, 7, and 14 days post PHx. (**D**) Liver to body weight percent of *let-7b/c2^Fl/Fl^* (n=11) and *let-7b/c2* LKO mice (n=10) 4, 7, and 14 days after PHx. All data in this figure are represented as mean ± SEM. \*p\<0.05, \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.09431.008](10.7554/eLife.09431.008)10.7554/eLife.09431.009Figure 3---figure supplement 2.Post-natal deletion of *let-7b/c2* also enhances liver regeneration.(**A**) Schema showing that *let-7b/c2 ^+/+^* and *let-7b/c2^Fl/Fl^ *mice were injected with AAV-Cre at 49 days of age, PHx was performed 7 days after viral injection, and tissues were collected 40 hr post PHx. (**B**) DNA gel showing excised *let-7b/c2* band in *let-7b/c2^Fl/Fl^* + AAV-Cre mice (n=5) but not in *let-7b/c2 ^+/+^* + AAV-Cre mice. (**C**) Percentage of resected liver/body weight ratios of *let-7b/c2 ^+/+^* + AAV-Cre (n=5) and *let-7b/c2^Fl/Fl^ +* AAV-Cre mice (n=5) at the time of PHx. (**D**) Liver/body weight ratios of the above mice 40 hr after PHx. (**E**) Ki-67 staining on resected and 40 hr post-PHx livers from the above mice (n=3 and 3). (**F**) Quantification of Ki-67-positive cells (n=2 and 2 mice; total of ten 40x fields/mouse were used for quantification). All data in this figure are represented as mean ± SEM. \*p\<0.05, \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.09431.009](10.7554/eLife.09431.009)

These LKO mice were healthy and showed normal liver/body weight ratios and histology at baseline ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). An identical amount of liver mass was resected from *let-7b/c2^Fl/Fl^* control and *let-7b/c2* LKO mice ([Figure 3C,D](#fig3){ref-type="fig"}), but LKO mice exhibited significant increases in liver mass and proliferation 40 hr after surgery ([Figure 3E--G](#fig3){ref-type="fig"}). Four and seven days after PHx, there were no differences in liver weights, indicating that other phases of regeneration were unaffected ([Figure 3---figure supplement 1C,D](#fig3s1){ref-type="fig"}). At fourteen days, the liver weight precisely achieved pre-surgery levels in control and LKO mice, indicating accelerated but not excessive regeneration ([Figure 3---figure supplement 1C,D](#fig3s1){ref-type="fig"}). There was no compensatory upregulation of other *let-7s* in pre- or post-PHx tissues ([Figure 3H](#fig3){ref-type="fig"}), supporting the concept that *let-7* is a dose-dependent regeneration suppressor.

Cre under the *Albumin* promoter is expressed in embryonic hepatoblasts that give rise to both hepatocyte and bile duct compartments ([@bib28], [@bib29]; [@bib45]; [@bib43]; [@bib22]), so developmental influences of *let-7* loss could have led to adult phenotypes. To define cell- and temporal-specific roles of *let-7b/c2*, we used adeno-associated virus expressing Cre (AAV8.TBG.PI.Cre.rBG, hereafter called \"AAV-Cre\"), known to mediate efficient gene excision in hepatocytes but never in biliary epithelial cells ([@bib47]) ([Figure 3---figure supplement 2A,B](#fig3s2){ref-type="fig"}). These adult and hepatocyte-specific conditional knockout mice also exhibited significantly enhanced regenerative capacity ([Figure 3---figure supplement 2C--F](#fig3s2){ref-type="fig"}). To test if proliferative effects are specific to particular *let-7* species, we knocked-down either *let-7a* or *let-7b* in SV40 immortalized hepatocytes (H2.35 cells) and found that both led to increased proliferation ([Figure 3I](#fig3){ref-type="fig"}). Collectively, our data shows that physiological *let-7* levels regulate the kinetics of adult liver regeneration by hepatocytes.

*let-7g* suppresses liver regeneration through insulin-PI3K-mTOR {#s2-4}
----------------------------------------------------------------

*let-7* was previously demonstrated to regulate the insulin-PI3K-mTOR pathway ([@bib49]; Frost and Olson, 2011), which is also important in liver regeneration ([@bib27]; [@bib2]; [@bib10]; [@bib6]). To avoid auto-regulatory feedback and compensation as confounding factors, we focused on liver tissues exposed to acute *let-7* gain or loss. In regenerating livers treated with *let-7g* mimic ([Figure 2I--K](#fig2){ref-type="fig"}), we found significant protein suppression of insulin receptor β, Igf1rβ, and Irs2, previously validated *let-7* targets at the top of the insulin pathway ([Figure 4A,B](#fig4){ref-type="fig"}) ([@bib49]). In addition to insulin signaling components, the expression of cell cycle genes (*Ccnb1, Cdc34*, and *Cdk8*) and *Map4k4* were also downregulated ([Figure 4C](#fig4){ref-type="fig"}). In mice with acute *let-7b/*c*2* deletion by AAV-Cre ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), there was a small increase in insulin receptor β protein levels ([Figure 4D,E](#fig4){ref-type="fig"}). Increased mTOR signaling was also evident in the increased phospho-S6K/Total S6K and phospho-S6/Total S6 ratios ([Figure 5E](#fig5){ref-type="fig"}).10.7554/eLife.09431.010Figure 4.*let-7g* suppresses liver regeneration through insulin-PI3K-mTOR.(**A**) Western blots of insulin receptor β, Igf1rβ, Irs2, and β-Actin in negative control or *let-7g* microRNA mimic treated liver tissues 40 hr after PHx. (**B**) Quantification of intensity of insulin receptor β, Igf1rβ, Irs2 (Image J). (**C**) Cell cycle gene expression in *let-7S21L* alone (n=4) and *LAP-let-7S21L* (n=4) livers before and 40 hr after PHx as determined by RT-qPCR. (**D**) Western blots of insulin receptor β, Igf1rβ, p-S6K, total S6K, β-Actin, p-S6 (Ser235/236), and total S6 in AAV-Cre treated *let-7b/c2* ^+/+^ and *let-7b/c2^Fl/Fl^* livers (n=5 and 5). (**E**) Quantification of intensity of insulin receptor β/β-Actin, p-S6K/total S6K, and p-S6/total S6, 40 hr after PHx (Image J). (**F**) Rapamycin treatment during and after PHx in *let-7b/c2^Fl/Fl ^*control and *let-7b/c2* LKO mice. Shown are liver weights 40 hr post PHx. (**G**) INK128 treatment during and after PHx in *let-7b/c2^Fl/Fl^* control and *let-7b/c2* LKO mice. Shown are liver weights 40 hr post PHx. (**H**) Western blots of p-S6K, total S6K, and β-Actin in *let-7b/c2^Fl/Fl^* control and *let-7b/c2* LKO livers treated with either vehicle or INK128 at 40 hr post PHx. All data in this figure are represented as mean ± SEM. \*p\<0.05, \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.09431.010](10.7554/eLife.09431.010)10.7554/eLife.09431.011Figure 5.Chronic high-dose *let-7g* causes hepatotoxicity and liver carcinogenesis.(**A**) Schema showing that *let-7S21L* control and *Rosa-rtTA; let-7S21L* mice were induced at 42 days of age and collected at 84 days. (**B**) Images showing the whole body, extremities, and livers of *Rosa-rtTA* (n=4) and *Rosa-let-7S21L* mice (n=3) given 1 mg/mL dox between 42 and 84 days of age. (**C**) Liver function tests: AST (U/L), ALT (U/L), and total bilirubin (mg/L) in these mice. (**D**) H&E staining of livers. (**E**) RT-qPCR of mature *let-7s* and other microRNAs in *let-7g* overexpressing mice (n=4 and 3). (**F**) **B**ody weight 3 days after injection of 2.0 mg/kg negative control or *let-7*g microRNA mimics packaged in C12-200 LNPs relative to pre-injection weight (n=5 and 4). (**G**) Liver function tests: AST (U/L) and ALT (U/L) in WT C57Bl/6 mice before and 3 days after mimic injection (n=5 and 4). (**H**) Mature *let-7* levels in wild-type C57Bl/6 mice treated with mimics as determined by RT-qPCR (n=5 and 4). (**I**) Kaplan-Meier curve for *Rosa-let-7S21L* induced with 1.0 g/L dox at 6 weeks old (n=15 and 17). (**J**) Gross images of the liver of *Rosa-let-7S21L* mice induced for 18 months. All data in this figure are represented as mean ± SEM. \*p\<0.05, \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.09431.011](10.7554/eLife.09431.011)10.7554/eLife.09431.012Figure 5---figure supplement 1.Data associated with Figure 5.(**A**) Body, liver, and liver/body weight ratios of control (n=4) and *Rosa-let-7S21L* (n=3) mice after 42 days of induction. (**B**) Gross image of *Rosa-rtTA* (non-induced) and *Rosa-miR26a-2* (induced) mice under 1.0 g/L dox for 42 days. (**C**) Liver function tests: AST (U/L), ALT (U/L), and total bilirubin (mg/L) (n=2 and 2) after induction. (**D**) H&E staining of *Rosa-rtTA* (non-induced) and *Rosa-miR26a-2* (induced) mice after induction. All data in this figure are represented as mean ± SEM. \*p\<0.05, \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.09431.012](10.7554/eLife.09431.012)

To determine if mTOR signaling is functionally relevant in LKO mice, we treated mice with rapamycin two hours prior to and immediately after PHx. Rapamycin abrogated differences in regenerating liver weights between control and LKO mice ([Figure 4F](#fig4){ref-type="fig"}), demonstrating that *let-7b/c2* loss promotes additional mTOR activation to enhance regeneration. Rapamycin's allosteric inhibition of mTOR can lead to pleiotropic and unpredictable effects due to cell-type specific and feedback related phenomena ([@bib36]). INK128 is a second generation mTOR inhibitor that directly competes with ATP at the catalytic domains of mTORC1/2, leading to more complete abrogation of 4EBP and S6K1 ([@bib12]). INK128, similar to rapamycin, completely abrogated the regenerative enhancement associated with *let-7b/c2* loss ([Figure 4G](#fig4){ref-type="fig"}). Analysis of p-S6K confirmed that mTOR is hyperactivated in LKO livers and that INK128 extinguishes the mTOR dependent phosphorylation of this substrate ([Figure 4H](#fig4){ref-type="fig"}). Similar results after rapamycin and INK128 indicated that mTOR and its substrates play an essential role in driving increased regeneration in the context of *let-7* suppression.

Chronic high-dose *let-7g* causes hepatotoxicity and liver carcinogenesis {#s2-5}
-------------------------------------------------------------------------

Since acute *let-7g* induction interferes with hepatocyte proliferation, we asked what the effects of chronic high-dose *let-7g* induction might be. To answer this question, we induced *let-7g* using *rtTA* under the control of the *Rosa* promoter, which drives higher expression than the *LAP* promoter ([Figure 5A](#fig5){ref-type="fig"}). These mice lost significant body weight and became jaundiced ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"} and [Figure 5](#fig5){ref-type="fig"}). Liver function tests indicated severe liver injury ([Figure 5C](#fig5){ref-type="fig"}) and histology showed prominent microvesicular steatosis, characterized by intra-cytoplasmic lipid droplets ([Figure 5D](#fig5){ref-type="fig"}), a finding associated with drug-induced liver injury, acute fatty liver of pregnancy, or Reye's syndrome in humans. Using this system, mature *let-7g* was overexpressed by more than twentyfold, as compared to ∼eightfold induction in the *LAP-let-7S21L* system ([Figure 5E](#fig5){ref-type="fig"}). Liver dysfunction was not seen after low-dose *let-7* overexpression in *LAP-let-7S21L* mice ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) or after high-dose *miR-26a-2* overexpression in *Rosa-rtTA; TRE-miR-26a-2* mice ([Figure 5---figure supplement 1B--D](#fig5s1){ref-type="fig"}), suggesting a dose and *let-7* microRNA specific effect.

Another possibility was that the *miR-21* loop of the *let-7S21L* construct saturated the microRNA biogenesis machinery, thus causing non-specific toxicity independent of the *let-7* seed sequence. To address this we again delivered a higher dose (2.0 mg/kg) of mature *let-7g* and control microRNA mimics, which do not harbor loops or tails, into wild-type mice. Mice receiving *let-7g* mimic lost significantly more weight ([Figure 5F](#fig5){ref-type="fig"}) and suffered hepatocyte destruction leading to increased AST/ALT levels ([Figure 5G](#fig5){ref-type="fig"}), while control mice remained healthy. Mimic delivery achieved a twelvefold increase of *let-7g* ([Figure 5H](#fig5){ref-type="fig"}). These results suggest that above certain doses *let-7* is incompatible with hepatocyte survival, and that *let-7's* anti-proliferative activities would interfere with normal tissue homeostasis.

When the *Rosa-let-7S21L* mice were induced chronically, approximately 50% of the mice survived the acute liver injury seen after dox induction ([Figure 5I](#fig5){ref-type="fig"}). Over the course of 18 months, 5 of 10 (50%) of these surviving mice developed large liver tumors, whereas only 1 of 12 (7.7%) of the non-induced mice had any tumors ([Figure 5J](#fig5){ref-type="fig"}). Chronic *let-7* overexpression likely caused hepatocyte toxicity and selected for pre-malignant hepatocytes that eventually become cancer. Our long-term experiments revealed the potential dangers of chronic *let-7* treatment, and the consequent disruption of the balance between tissue regeneration, degeneration, and cancer risk.

Discussion {#s3}
==========

The role of *let-7*s in adult animal physiology is unclear in part because the redundancy of this large microRNA family has made loss of function studies challenging. Deep redundancy of multiple highly conserved genes raises the possibility that dose regulation is important. Despite this, overexpression has been helpful in uncovering physiological functions of *let-7* ([@bib49]; [@bib8]; [@bib33]; [@bib26]; [@bib21]). Using overexpression tools, we have shown that *let-7* suppression is a fundamental requirement for *MYC*-mediated liver transformation, and that *let-7* is capable of counteracting strong oncogenic drivers in vivo. However, one negative consequence of raising the level of *let-7* expression is a limitation in the ability to regenerate after major tissue loss. More surprisingly, our knockout mouse model showed that the loss of two out of the ten *let-7* members in the liver resulted in improved liver proliferation and regeneration. These data suggest a lack of complete redundancy between *let-7* microRNA species, but rather a precisely regulated cumulative dose that when increased or decreased, leads to significant alterations in regenerative capacity.

The knowledge that *let-7* suppresses both normal and malignant growth will have particular relevance to malignancies that arise from chronically injured tissues. In these tissues, winners of the competition between cancer and host cells might ultimately dictate whether organ failure or tumor progression ensues. It has been thought that one key advantage of using microRNAs therapeutically is that they are already expressed at high levels in normal tissues, thus making increased dosing likely to be safe and tolerable. Surprisingly, we showed that chronic *let-7* overexpression caused hepatotoxicity, disrupted tissue homeostasis, ultimately leading to carcinogenesis. This is likely due to the high levels of overexpression achieved in the *Rosa-rtTA* transgenic system, as opposed to the lower dose in the *LAP-tTA* system. These high doses are likely to be toxic to hepatocytes, a phenomena compounded by the fact that excess *let-7* impairs proliferation in surviving cells that might serve to replenish lost tissues. Eventually, certain clones must epigenetically or genetically evolve to evade *let-7* growth inhibition in order to transform.

It is also interesting that *let-7* overexpression led to dramatically different outcomes in distinct cancer contexts. While dose is most likely the critical variable between the *Rosa-rtTA* and *LAP-tTA* systems, *Rosa-rtTA* does induce expression in cells other than hepatocytes and bile duct epithelia, leaving the possibility that non-cell autonomous influences of *let-7* overexpression play a role in liver injury and cancer development. A more interesting possibility would be if distinct genetic subtypes of cancer respond differently to *let-7* overexpression. Since *let-7* has been conceptualized as a general tumor suppressor, it is surprising that it can cause opposing phenotypes in distinct cancer models. *MYC* liver cancers show a dramatic suppression of *let-7*, rendering it especially sensitive to *let-7* replacement. Tumors or tissues with more normal levels of *let-7* might not respond to increases in *let-7*. Alternatively, the growth of other cancer models may not depend on the overproduction of *let-7* target genes/proteins. *let-7* overexpression in these contexts would probably not elicit growth suppression, but may instead exacerbate tissue injury. It would be interesting to evaluate the effects of *let-7* overexpression in hepatocellular carcinomas caused by different driver mutations. Together, our data suggest that *let-7* therapy directed at hepatocellular carcinomas could be risky, given that most of these cancers occur in severely compromised, cirrhotic livers ([@bib46]).

We speculate that the total dose of *let-7* is evolutionarily determined via regulation of the expression levels of individual *let-7* members, and is postnatally maintained at a level that can suppress cancer, but which also allows for adequate levels of mammalian regenerative capacity. Clearly, *let-7* levels are not static throughout life, since *let-7* levels are dynamic after environmental perturbations. However, when baseline *let-7* levels are altered permanently by genetic means, compromises in tumor suppression or tissue regeneration were revealed. Our study underscores the importance of regulating appropriate levels of this small RNA to maintain health during times of regenerative stress.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

All mice were handled in accordance with the guidelines of the Institutional Animal Care and Use Committee at UTSW. *MYC* tumor models and the *LAP-let-7S21L* inducible mice were carried on a 1:1 FVB/C57Bl/6 strain background. Please see ([@bib26]) for more details about the *let-7b/c2* floxed mice, which are on a C57Bl/6 background. The chronically injured *let-7* inducible mice were on a mixed B6/129 background. All experiments were done in an age and sex controlled fashion unless otherwise noted in the figure legends.

Partial hepatectomy {#s4-2}
-------------------

Two-thirds of the liver was surgically excised as previously described ([@bib23]).

RNA extraction and RT-qPCR {#s4-3}
--------------------------

Total RNA was isolated using Trizol reagent (Invitrogen). For RT-qPCR of mRNAs, cDNA synthesis was performed with 1 ug of total RNA using miScript II Reverse Transcription Kit (Cat. \#218161, Qiagen). Gene expression levels were measured using the ΔΔCt method as described previously ([@bib48]).

Western blot assay {#s4-4}
------------------

Mouse liver tissues were ground with a pestle and lysed in T-PER Tissue Protein Extraction Reagent (Thermo Scientific Pierce). Western blots were performed in the standard fashion. The following antibodies were used: Anti-Insulin receptor β (Cell Signaling \#3025), Anti-Igf1rβ (Cell Signaling \#9750), Anti-Irs2 (Cell Signaling \#3089), Anti-total S6K (Cell Signaling \#9202), Anti-p-S6K (Cell Signaling \#9205), Anti-total S6 (Cell Signaling \#2217), Anti-p-S6 Ser235/236 (Cell Signaling \#2211), Anti-mouse β-Actin (Cell Signaling \#4970), Anti-rabbit IgG, HRP-linked Antibody (Cell Signaling \#7074) and Anti-mouse IgG, HRP-linked Antibody (Cell Signaling \#7076).

Histology and immunohistochemistry {#s4-5}
----------------------------------

Tissue samples were fixed in 10% neutral buffered formalin or 4% paraformaldehyde (PFA) and embedded in paraffin. In some cases, frozen sections were made. Immunohistochemistry was performed as previously described ([@bib48]). Primary antibodies used: Ki-67 (Abcam \#ab15580). Detection was performed with the Elite ABC Kit and DAB Substrate (Vector Laboratories), followed by Hematoxylin Solution counterstaining (Sigma).

Liver function tests {#s4-6}
--------------------

Blood samples (∼50 ul) were taken retro-orbitally in heparinized tubes. Liver function tests were analyzed by the UTSW Molecular Genetics core.

Viral Cre excision {#s4-7}
------------------

100 μL of AAV8.TBG.PI.Cre.rBG (University of Pennsylvania Vector Core) was retro-orbitally injected at a titer of 5 x× 10^10^ genomic particles to mediate 90%---100% Cre excision.

Cell culture and in vitro antiMiR experiments {#s4-8}
---------------------------------------------

The H2.35 cell line was directly obtained from ATCC and has been cultured for less than 6 months. The cells were authenticated by ATCC using Short Tandem Repeat (STR) DNA profiling. Cells were cultured in DMEM with 4% (vol/vol) FBS, 1x Pen/Strep (Thermo Scientific) and 200 nM Dexamethasone (Sigma). Cells were transfected with control (Life Technologies Cat. AM17010), *let-7a* (Life Technologies Cat. \#4464084-Assay ID MH10050), or *let-7g* (Life Technologies Cat. \#4464084-Assay ID MH11050) miRVana antiMiRs. AntiMiRs were packaged by RNAiMAX (Invitrogen) and transfected into H2.35 cells cultured in 96-well plates at a concentration of 50 nM. The number of viable cells in each well was measured at 2 and 3 days after transfection using CellTiter-Glo Luminescent Cell Viability Assay (Promega Cat. \#G7570).

In vivo microRNA mimic experiments {#s4-9}
----------------------------------

For in vivo experiments, formulated C12-200 lipidoid nanoparticles (LNPs) were used to package either Control (Life Technologies Cat. \#4464061) or *let-7g* (Life Technologies Cat. 364 \#4464070-Assay ID MC11758) miRVana mimic at either 0.5 or 2 mg/kg and delivered intravenously through the tail vein. LNPs were formulated following the previously reported component ratios ([@bib20]) with the aid of a microfluidic rapid mixing instrument (Precision Nanosystems NanoAssemblr) and purified by dialysis in sterile PBS before injection.

In vivo drug treatments {#s4-10}
-----------------------

Rapamycin (LC Biochem) was dissolved in 25% ethanol/PBS and then injected at 1.5 mg/kg 2 hr prior to and 20 hr after PHx. INK128 (LC Biochem) was formulated in 5% polyvinylpropyline, 15% NMP, 80% water and administered by oral gavage at 1 mg/kg 2 hr prior to and 20 hr after PHx.

MicroRNA sequencing {#s4-11}
-------------------

Female CD1 mice were treated with 3 mg/kg TCPOBOP in DMSO-corn oil by gavage ([@bib37]), sacrificed at 3, 6, 9, 12, and 18 hr after treatment, and compared to untreated controls. Replicate libraries were made from two individual mice for each condition. RNA was purified with the Qiagen miRNeasy Mini kit. Small RNA libraries were constructed using an Illumina Truseq Small RNA Sample Prep Kit. 12 indexed libraries were multiplexed in a single flow cell lane and received 50 base single-end sequencing on an Illumina HiSeq 2500 sequencer. Sequence reads were aligned to mm9 using Tophat and quantified with Cufflinks by the FPKM method ([@bib40]). Data for each experimental condition represent the average values from two libraries.

Statistical analysis {#s4-12}
--------------------

The data in most figure panels reflect multiple experiments performed on different days using mice derived from different litters. Variation is always indicated using standard error presented as mean ± SEM. Two-tailed Student\'s *t*-tests (two-sample equal variance) were used to test the significance of differences between two groups. Statistical significance is displayed as p\<0.05 (\*) or p\<0.01 (\*\*) unless specified otherwise. In all experiments, no mice were excluded form analysis after the experiment was initiated. Image analysis for the quantification of cell proliferation, cell death, and fibrosis were blinded.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled \"Precise *Let-7* expression levels balance organ regeneration against tumor suppression\" for peer review at *eLife*. Your submission has been favorably evaluated by Fiona Watt (Senior editor), a Reviewing editor, and two reviewers.

The following individual responsible for the peer review of your submission has agreed to reveal his identity: Frank Slack (peer reviewer). A further reviewer remains anonymous.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

In the manuscript entitled \"Precise *Let-7* expression levels balance organ regeneration against tumor suppression\" Wu and colleagues utilize transgenic overexpression and liver-specific knockout of *Let-7* to assess the consequences of *Let-7* dysregulation in the setting of *MYC*-driven carcinogenesis and during liver regeneration after partial hepatectomy. The authors find that moderate *Let-7* overexpression blocks MYC-driven hepatoblastoma formation and inhibits liver regeneration after partial hepatectomy. During liver regeneration, *Let-7* overexpression alters steady state levels of various metabolites. Further, *Let-7* regulates the insulin-mTOR pathway after regeneration. Finally, extreme *Let-7* overexpression causes liver injury and liver carcinogenesis.

All reviewers found this work to be innovative and important, noting particularly the likely impact on the field of demonstrating the functional role of *Let-7* regulation during carcinogenesis and liver repair and the potential negative effects of high dose *Let-7* on normal liver function. However, two reviewers expressed significant concerns about the rather expansive scope of the manuscript in its current form, which causes the work to appear somewhat superficial and difficult to follow in places. The authors are strongly encouraged to consider how they may address this issue in their revision, perhaps by separating some of the multiple, intertwined stories or by providing clearer connections between the various observations that are reported.

Essential revisions:

1\) Please revise the manuscript to provide more focus on the major conclusions and message and a clearer, more streamlined description of the experiments and data.

2\) Some conclusions presented appear to be stronger than others, and the paper would benefit from inclusion of relevant experimental caveats. For example, the partial hepatectomy studies only examine one time point, at 40 hours post resection, thereby only investigating the initial phase of hepatocyte proliferation, rather than also the subsequent phase of vascular-driven liver remodeling. It is possible that *Let-7* is more dynamically regulated and active in both phases. Similar concerns apply to the metabolomics studies, which, while innovative, are problematic in that they represent a snap shot of the metabolic state at one time point. They provide no assessment of metabolite flux, which would require more extensive labeling studies. Further, the increase in nucleotides, for example, could well be due to increased biosynthesis, but could also be due to a block in nucleotide utilization. If rapid cell proliferation is required for liver regeneration, requiring rapid DNA synthesis, would DNA assembly be the rate-limiting step, causing accumulation of nucleotides? Also, would it be informative to correlate metabolite changes in the glycolysis or nucleotide biosynthesis pathways with expression changes of relevant enzymes? Please address these issues experimentally or by inclusion of relevant discussion and caveats.

3\) The role of mTOR in liver regeneration has been described, and the connection to the *Let-7* pathway is intriguing, as is the fact that rapamycin decreases liver recovery. However, the pleiotropic effects of rapamycin are also well-described, and should be noted. The use of more specific agents (e.g. Torin) or genetic methods, if available, might also be desirable for a more comprehensive assessment.

4\) Please comment on whether differences in cellular context (i.e., oncogenetic background) in addition to or instead of *Let7g* levels may explain the different outcomes in the *myc*-driven vs. spontaneous tumor models.

10.7554/eLife.09431.016

Author response

*All reviewers found this work to be innovative and important, noting particularly the likely impact on the field of demonstrating the functional role of* Let-7 *regulation during carcinogenesis and liver repair and the potential negative effects of high dose* Let-7 *on normal liver function. However, two reviewers expressed significant concerns about the rather expansive scope of the manuscript in its current form, which causes the work to appear somewhat superficial and difficult to follow in places. The authors are strongly encouraged to consider how they may address this issue in their revision, perhaps by separating some of the multiple, intertwined stories or by providing clearer connections between the various observations that are reported. Essential revisions: 1) Please revise the manuscript to provide more focus on the major conclusions and message and a clearer, more streamlined description of the experiments and data.*

We have revised the paper so that it is clearer and more streamlined. Redundant data was removed. For example, the experiment involving *MYC* +/- *let-7S21L* induction at 4 weeks as opposed to 2 weeks of age, which revealed similar findings, was removed. The metabolism data was removed as suggested by the editors and reviewers. The language in many sections was also shortened and clarified.

*2) Some conclusions presented appear to be stronger than others, and the paper would benefit from inclusion of relevant experimental caveats. For example, the partial hepatectomy studies only examine one time point, at 40 hours post resection, thereby only investigating the initial phase of hepatocyte proliferation, rather than also the subsequent phase of vascular-driven liver remodeling. It is possible that* Let-7 *is more dynamically regulated and active in both phases.*

It is possible that *let-7* is dynamically regulated and important during multiple mechanistically independent phases of liver regeneration, although it is unlikely given the *let-7* expression data. [Figure 2A](#fig2){ref-type="fig"} shows that *let-7* was significantly altered only during the period shortly after hepatectomy and reverted back to baseline levels at around 40 hours.

Vascular-driven liver remodeling was previously shown to be influential 4-7 days after partial hepatectomy (Ding et al. Nature 2010). To completely exclude the possibility that this mechanism is influenced by *let-7*, we assessed the liver regeneration at 4, 7 and 14 days post partial hepatectomy. In both loss and gain of function models, there were no significant differences in regenerated liver mass ([Figure 2--figure supplement 1E,F](#fig2s1){ref-type="fig"} and [Figure 3--figure supplement 1C,D](#fig3s1){ref-type="fig"}). These results support the idea that *let-7* expression changes lead to alterations in the initial, but not subsequent phases of liver regeneration after partial hepatectomy.

*Similar concerns apply to the metabolomics studies, which, while innovative, are problematic in that they represent a snap shot of the metabolic state at one time point. They provide no assessment of metabolite flux, which would require more extensive labeling studies. Further, the increase in nucleotides, for example, could well be due to increased biosynthesis, but could also be due to a block in nucleotide utilization. If rapid cell proliferation is required for liver regeneration, requiring rapid DNA synthesis, would DNA assembly be the rate-limiting step, causing accumulation of nucleotides? Also, would it be informative to correlate metabolite changes in the glycolysis or nucleotide biosynthesis pathways with expression changes of relevant enzymes? Please address these issues experimentally or by inclusion of relevant discussion and caveats.*

As suggested by the editors and reviewers, we excluded the metabolomics data from this manuscript in an effort to focus on the major findings of the paper.

*3) The role of mTOR in liver regeneration has been described, and the connection to the* Let-7 *pathway is intriguing, as is the fact that rapamycin decreases liver recovery. However, the pleiotropic effects of rapamycin are also well-described, and should be noted. The use of more specific agents (e.g. Torin) or genetic methods, if available, might also be desirable for a more comprehensive assessment.*

Rapamycin has pleiotropic and cell-type dependent effects. This is partly because it acts allosterically through FKBP12 rather than mTOR itself, and thus does not completely inhibit mTORC1 and mTORC2. As a result, variable inhibition of mTORC1 substrates can lead to incomplete protein synthesis inhibition via p-4EBP. In contrast, second generation ATP-competitive mTOR kinase inhibitors such as Torin and INK128 directly antagonize mTORC1/2 complexes and thus are more potent and specific inhibitors (Hsieh et al., 2012).

To confirm the rapamycin results with a second compound, and to examine the impact of more potent mTOR blockade, we performed partial hepatectomy in *let-7b/c* LKO mice treated with INK128. Torin1 was not used in part because of poor mouse microsome stability and a short *in vivo* half-life (Liu and Gray et al., Bioorg Med Chem Lett. 2011), and because we have had previous successes using INK128 in vivo.

INK128, similar to rapamycin, completely abrogated the regenerative enhancement associated with *let-7* loss ([Figure 4G](#fig4){ref-type="fig"}). p-S6K western blots confirmed that mTOR is hyperactivated in LKO livers and that INK128 extinguishes mTOR activity ([Figure 4H](#fig4){ref-type="fig"}). Identical results after rapamycin and INK128 indicated that the mTOR signaling pathway and its substrates (especially S6K) play an essential role in driving increased regeneration in the context of *let-7* suppression.

*4) Please comment on whether differences in cellular context (i.e., oncogenetic background) in addition to or instead of* Let7g *levels may explain the different outcomes in the* myc*-driven vs. spontaneous tumor models.*

Additional comments/clarification from the reviewers:

*The authors use 2 different tumor models to assess the effects of* let-7 *overexpression on tumorigenesis in the liver, and they observe two different outcomes. In the current manuscript, they attribute the difference in outcome solely to differences in expression levels of* let-7 *(8 fold in one model and 20-fold in the other). However, there are many other differences in the oncogenetic backgrounds of the models that also could contribute to or account for the differences. For instance, in one case where* let-7 *reduces tumor burden, tumors arise due to strong induction of oncogenic* Myc*; these tumors have a 3-5 month latency. In the other case, tumors arise spontaneously, with unknown oncogenic mutations, and show an 18 mo. latency. Thus, an alternative interpretation of the data is that* let-7 *overexpression in* Myc *overexpressing tumors is tumor suppressive whereas* let-7 *overexpression in tumors lacking* Myc *overexpression is tumor promoting.*

*This would be analogous to observations in* Drosophila *indicating that oncogenic Ras converts TNF signaling from anti- to pro-oncogenic (see, e.g., Cordero et al. Dev. Cell 18:999, 2010). Or, it may be that* let-7 *overexpression in young mice (\<6 mo) is tumor suppressive whereas* let-7 *overexpression in aged mice (\>12mo.), which have acquired additional age-associated genetic, epigenetic and microenvironmental alterations, is tumor promoting. One could test this experimentally, by using the* RosaLet7S21L *system in the* LAP-tTA; TRE-Myc *background, but as this would be a rather time-consuming experiment, the authors may instead wish simply to discuss more clearly the other differences in the models that might contribute to the different outcomes, rather than attributing outcomes only to* let-7 *expression levels.*

We agree that cellular context or oncogenetic background in addition to *let-7* dose may indeed contribute to the different cancer outcomes. We did not to make the claim that *let-7* overexpression is effective in *MYC* cancers solely because it is expressed at low doses. We only stated that *let-7* dose is a critically important variable in liver injury (in the absence of *MYC*). As a key piece of evidence, we directly compared low and high dose *let-7* overexpression in normal livers. Long-term low dose *let-7* overexpression in *LAP-let-7S21L* mice ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) never resulted in liver dysfunction or tumor formation. This was emphasized and clarified in the text.

Age should also be excluded as a possibility, since high dose *let-7* was induced by *Rosa-rtTa* from 2 or 4 weeks onward, mirroring the *MYC + let-7* induction times. There are however caveats to consider. The *LAP* and *Rosa* promoters induce expression in different cells at different levels, resulting in complex non-cell autonomous influences that might play a role in liver cancer development. We have commented on this possibility in the revised paper.

Certainly, *MYC* tumors may be particularly sensitive to *let-7* overexpression because of its specific oncogenetic context. *MYC*-driven liver cancers show a dramatic suppression of *let-7*; other tumor or tissue contexts may not share this extent of *let-7* suppression. It would make sense that this context is especially sensitive to *let-7* replacement, whereas tumors or tissues with normal levels of *let-7* might not respond to *let-7* increases. Alternatively, other cancer models may not depend on the overproduction of *let-7* target genes/proteins. Overexpressing *let-7* in those contexts would probably not suppress growth, but may instead exacerbate tissue injury. We have not had time to thoroughly evaluate other mouse models of liver cancer, although this would clearly be interesting.

Unfortunately, we have not had time to test high and low dose *let-7* expression in the context of *MYC* liver cancers. This is a difficult experiment for our transgenic systems because dose titration of *let-7* will also influence the dose of *MYC* (both are controlled by tet sensitive promoters), which is known to also influence tumor biology.

We have included a paragraph in the Discussion stating that it is possible that oncogenetic differences underlie the ways in which *let-7* impacts cancer biology.

[^1]: These authors contributed equally to this work.
